MFDS — authorised 16 June 2023
- Marketing authorisation holder: SPECTRUM PHARMS
- Status: likely_approved
🇰🇷 ROLVEDON in South Korea
MFDS authorised ROLVEDON on 16 June 2023
Marketing authorisation
ROLVEDON in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in South Korea
Frequently asked questions
Is ROLVEDON approved in South Korea?
Yes. MFDS authorised it on 16 June 2023.
Who is the marketing authorisation holder for ROLVEDON in South Korea?
SPECTRUM PHARMS holds the South Korean marketing authorisation.